多发性硬化患者脑脊液蛋白质组学研究

目的 探讨多发性硬化(MS)发病的分子机制并寻找其脑脊液(CSF)蛋白质标志物.方法 对MS患者与紧张型头痛患者各6例的CSF蛋白质组学进行比较研究.将浓缩的CSF去除高丰度蛋白后行双向凝胶电泳,对凝胶图谱进行图像分析,探寻差异性蛋白点并经肽质量指纹质谱技术鉴定蛋白质点.结果 MS患者38种蛋白质的表达与对照组比较差异有统计学意义(P<0.05),部分差异性蛋白质经鉴定为白蛋白单体CRA_n、ATP合成酶、普通转录因子IIH、白蛋白单体CRA_j、四连接素、结合珠蛋白、丛生蛋白、富亮氨酸α-2糖蛋白、视黄醇结合蛋白与甲状腺素结合蛋白.结论 MS患者CSF多种蛋白质表达差异,可能存在能量代谢异常、炎症反应和组织修复机制.     

一氧化氮与多发性硬化

一氧化氮参与了多发性硬化的病理生理学过程,对MS有促进和抑制的双重作用。文章对NO促进MS病情发展和缓解的作用及机制作了综述。     

脑脊液在多发性硬化诊断和研究中的意义

尽管近年来神经影像学技术如头颅ＣＴ和ＭＲＩ的长足进步，为多发性硬化（ＭＳ）临床诊断提供了有力的手段，但脑脊液（ＣＳＦ）检查在ＭＳ临床和研究方面的重要作用仍然是其他方法无法取代的。它不仅为ＭＳ的诊断和鉴别诊断提供依据，而且ＣＳＦ中免疫细胞和免疫分子的变...     

一氧化氮在多发性硬化中的作用及机制

一氧化氮（Nitric oxide,NO）自1987年被发现开始,在许多疾病中起了很大作用,包括多发性硬化（multiple sclerosis,MS）.NO对MS有促进和抑制的双重作用.本文对NO促进MS病情发展和缓解的作用及机制作一综述.     

多发性硬化患者脑脊液sIL-2R水平变化的研究

目的：探讨可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）在多发性硬化（ＭＳ）发病机理中的作用及其临床意义。方法：采用双抗体夹心ＥＬＩＳＡ法对４４例ＭＳ患者脑脊液ｓＩＬ－２Ｒ水平进行了检测。结果：ＭＳ组脑脊液ｓＩＬ－２Ｒ水平显著高于正常对照组,脑脊液ｓＩＬ－２Ｒ水平变化与ＭＳ患者疾病活动状态及病残程度密切相关。结论：ＭＳ患者体内Ｔ淋巴细胞处于活化状态,ｓＩＬ－２Ｒ在ＭＳ发病机理中发挥着重要作用,检测脑脊液ｓ     

多发性硬化患者血清及脑脊液的神经节苷酯抗体检测

目的 观察多发性硬化（MS）患者血清及脑脊液（CSF）中神经节苷抗体的分布，研究其在MS发病过程中的作用。方法 采用改良Marcus法检测20例MS患者血清和CSF神经节苷酯抗体的水平。结果 20例MS患者CSF和血清神经节苷酯抗体阳性率分别为75％，65％；和对照组比较均有显著性差异（P＜0．01）。结论 神经节苷酯抗体与参与了MS的发病过程。     

多发性硬化脑脊液检查的研究进展

多发性硬化(MS)是中枢神经系统(CNS)的自身免疫性疾病，具有时间和空间多发性。由于MS的异质性，给临床早期诊断带来了一定的困难。近年来，尽管神经影像学技术，特别是磁共振技术有了长足发展，可以通过不同序列成像，早期诊断MS，监测MS的疗效。但是脑脊液(CSF)检查，在MS临床研究中的重要作用仍是其他检查方法不可取代的，它不仅为MS的诊断和鉴别诊断提供依据，而且对于监测治疗效果、探讨发病机制和寻找新的治疗方法也有重要的意义。现对MSCSF检查的研究进展综述如下。     

多发性硬化患者血清和脑脊液中sICAM-1含量的检测及其临床意义

近年来研究表明,细胞间粘附分子（ＩＣＡＭ１）在多发性硬化（ＭＳ）发病机制中的作用已引起学者们的广泛关注。我们测定了ＭＳ患者血清和脑脊液（ＣＳＦ）中可溶性ＩＣＡＭ１（ｓＩＣＡＭ１）的含量变化,旨在探讨ｓＩＣＡＭ１在ＭＳ发病中的作用。资料：ＭＳ组...     

多发性硬化患者血清和脑脊液Epstein-Barr病毒抗体检测的意义

目的探讨多发性硬化(MS)患者血清和脑脊液(CSF)中EpsteinBarr(EB)病毒IgG抗体检测的意义。方法采用酶联免疫吸附法检测MS患者65例、其他神经科疾病(OND组)患者71例、非神经科疾病(NND组)患者42例的血清和CSF中EB病毒核抗原、壳抗原和早期抗原的IgG抗体,并进行分析比较。根据血清抗体检测结果的组合,分析各组中病毒初次感染、既往感染和病毒重新激活的情况。结果3组患者血清EB病毒核抗原、壳抗原IgG抗体阳性率均>90%,差异无显著性(均P>0.05)。MS组EB病毒早期抗原IgG抗体阳性率(46.2%)明显高于其他两组(18.3%,9.5%,均P<0.05)。MS组病毒感染重新激活的比率(46.2%)明显高于其他两组(18.3%,9.5%,均P<0.05)。3组CSF病毒抗体阳性率差异无显著性(均P>0.05)。结论MS患者活动性的EB病毒感染较多,EB病毒感染重新激活的比例很高。     

多发性硬化脑脊液寡克隆区带的研究进展

<正> 脑脊液(cerebrospinal fluid,CSF)寡克隆区带(oligoclonalbands,OB)的出现是诊断多发性硬化(multiple sclerosis,MS)的一项指标,提示中枢神经系统内存在体液免疫反应,是检测中枢神经系统亚急性、慢性炎性病变鞘内免疫球蛋白合成的最     

动脉瘤性蛛网膜下腔出血患者脑脊液中一氧化氮浓度的动态变化

目的探讨蛛网膜下腔出血后脑脊液中一氧化氮浓度的动态变化及其与脑血管痉挛的关系。方法采集57例动脉瘤性蛛网膜下腔出血(aSAH)患者脑脊液标本(采集时间为入院后即刻,出血后第3、5、7、10、14天),采用镉粒还原法检测脑脊液中NO浓度。结果出血后第3天脑脊液中NO浓度即有明显降低(P<0.05),在出血后第7～10天达到最低(P<0.01),而后逐渐升高。症状性脑血管痉挛患者NO浓度明显低于未痉挛者及无症状的脑血管痉挛患者。结论症状性脑血管痉挛的发生与脑脊液中NO浓度降低有一定相关性。     

肌萎缩侧索硬化症脑脊液生物学标志物的研究

肌萎缩侧索硬化症(ALS)是一种以选择性运动神经元变性为特征的神经退行性疾病.其病因和发病机制目前仍不明确,且缺乏客观的诊断标准和有效的治疗手段.脑脊液(CSF)能反映中枢神经系统病理生理改变,进行CSF中ALS生物学标志物的筛选将有助于疾病的诊断,为ALS发病机制的探讨提供线索.本文就近年来对ALS患者CSF中生物学标志物的研究作介绍.     

Interleukin-6 Levels in the Cerebrospinal Fluid of Patients with Multiple Sclerosis

Abstract: :We developed the competitive enzyme-linked immunosorbent assay for interleukin-6 (IL-6). The detection limit was 30 pg per ml. Using this method, we examined the IL-6 levels in the cerebrospinal fluid of 10 patients with multiple sclerosis (MS) and 12 age-matched normal controls. IL-6 was detected in 6 out of 10 patients with MS. There was no significant correlation between the IL-6 levels and other parameters, including IgG, IgG index, cell counts, total protein and albumin in the CSF. Our results suggest that IL-6 detected in the MS-CSF may have no correlation to the immunological processes.     

Multiple Sclerosis and Peripheral Multifocal Demyelinating Neuropathies Occurring in a Same Patient

The co-occurrence of multiple sclerosis and peripheral demyelinating neuropathy is rare. It has been disputed whether these are pathologically related or coincidental findings. We report a 36-year-old woman who presented with diplopia, right facial palsy and left-sided weakness. Brain magnetic resonance imaging showed a lesion indicative of central demyelinating disease. Nerve conduction studies revealed peripheral multifocal demyelinating neuropathies. We suggest that the central and the peripheral lesions may be continua of a demyelinating process.     

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis

Data regarding effectiveness and safety of ocrelizumab in the post-marking setting are lacking. The aim of our study was to provide effectiveness and safety data of ocrelizumab treatment in patients with relapsing–remitting (RR-) and progressive multiple sclerosis (PMS) and to evaluate clinical and immunological predictors of early treatment response. In this single-center prospective observational study, we investigated effectiveness outcomes (time-to-confirmed disability worsening, time-to-first relapse, time-to-first evidence of MRI activity and time-to-first evidence of disease activity), clinical and immunological predictors of early treatment response, and incidence of adverse events (AEs). One hundred and fifty-three subjects were included (93 RRMS; 84 females). Median follow-up was 1.9 (1.3–2.7). At 2-year follow-up (FU), disability worsening-free survival were 90.5%, 64.7%, and 68.8% for RRMS, primary-progressive MS (PPMS), and secondary-progressive MS (SPMS) patients, respectively. At 2-year FU, 67.1%, 72.7%, and 81.3% of patients with RRMS, PPMS, and SPMS were free of MRI activity, with NEDA-3 percentages of 62.1%, 54.6%, and 55.1%, respectively. Lower baseline EDSS was independently associated with a reduced risk of disability worsening (HR(95%CI) = 1.45(1.05–2.00), p = 0.024) and previous treatment exposure was independently associated with increased probability of radiological activity (HR = 2.53(1.05–6.10), p = 0.039). At 6-month FU, CD8 + cell decrease was less pronounced in patients with inflammatory activity (p = 0.022). Six patients (3.9%) discontinued ocrelizumab due to severe AEs. Our findings suggest that ocrelizumab is an effective treatment in real-world patients with RRMS and PMS, with a manageable safety profile. Better outcomes were observed in treatment-naïve patients and in patients with a low baseline disability level. Depletion of CD8 + cells could underlie early therapeutic effects of ocrelizumab.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13311-021-01104-8.     

多发性硬化患者血清和脑脊液中白细胞介素-6的变化及其意义

本研究应用生物学方法检测27例多发性硬化（MS）患者血清和脑脊液（CSF）白细胞介素-6（IL－6）水平，以探讨IL－6在MS发病中的作用。结果显示MS患者血清IL-6水平显著高于其他非炎症性神经病（NIND）组及正常对照（NC）组，其CSFIL－6水平亦显著高于NIND组；但MS患者血清与CSFIL-6水平不呈线性相关，血清IL-6水平随病情稳定而下降。本研究结果提示IL－6可能参与MS的免疫病理过程。